GetTopicDetailResponse(id=52d91e27773, topicName=Teprotumumab, introduction=Teprotumumab, content=null, image=null, comments=4, allHits=1127, url=https://h5.medsci.cn/topic?id=17277, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=50078, tagList=[TagDto(tagId=50078, tagName=Teprotumumab)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1598456, encodeId=32fa159845618, content=<a href='/topic/show?id=52d91e27773' target=_blank style='color:#2F92EE;'>#Teprotumumab#</a>, objectTitle=2019美國(guó)甲狀腺學(xué)會(huì)ATA：臨床試驗(yàn)證實(shí)Teprotumumab可顯著改善甲狀腺眼病的眼脹、復(fù)視和炎癥, objectType=article, longId=182365, objectId=732918236572, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=732918236572, replyNumber=0, likeNumber=89, createdTime=2019-11-06, rootId=0, userName=lhlxtx, userId=13c418593236, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=732918236572, moduleTitle=2019美國(guó)甲狀腺學(xué)會(huì)ATA：臨床試驗(yàn)證實(shí)Teprotumumab可顯著改善甲狀腺眼病的眼脹、復(fù)視和炎癥, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=732918236572)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598455, encodeId=42011598455d2, content=<a href='/topic/show?id=52d91e27773' target=_blank style='color:#2F92EE;'>#Teprotumumab#</a>, objectTitle=2019年美國(guó)臨床內(nèi)分泌學(xué)家協(xié)會(huì)（AACE）大會(huì)：Teprotumumab治療甲狀腺眼病的III期試驗(yàn)結(jié)果, objectType=article, longId=164221, objectId=3dc6164221e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc6164221e6, replyNumber=0, likeNumber=89, createdTime=2019-04-15, rootId=0, userName=lhlxtx, userId=13c418593236, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc6164221e6, moduleTitle=2019年美國(guó)臨床內(nèi)分泌學(xué)家協(xié)會(huì)（AACE）大會(huì)：Teprotumumab治療甲狀腺眼病的III期試驗(yàn)結(jié)果, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=3dc6164221e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598454, encodeId=ffb2159845435, content=<a href='/topic/show?id=52d91e27773' target=_blank style='color:#2F92EE;'>#Teprotumumab#</a>, objectTitle=Horizon的teprotumumab治療活動(dòng)性甲狀腺眼病III期臨床試驗(yàn)大獲成功, objectType=article, longId=161504, objectId=8f841615044d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f841615044d, replyNumber=0, likeNumber=79, createdTime=2019-03-03, rootId=0, userName=lhlxtx, userId=13c418593236, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f841615044d, moduleTitle=Horizon的teprotumumab治療活動(dòng)性甲狀腺眼病III期臨床試驗(yàn)大獲成功, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=8f841615044d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1598453, encodeId=cc59159845398, content=<a href='/topic/show?id=52d91e27773' target=_blank style='color:#2F92EE;'>#Teprotumumab#</a>, objectTitle=NEJM： Teprotumumab用于甲狀腺相關(guān)眼病, objectType=article, longId=97836, objectId=e6c99e836f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6c99e836f0, replyNumber=0, likeNumber=94, createdTime=2017-05-06, rootId=0, userName=lhlxtx, userId=13c418593236, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6c99e836f0, moduleTitle=NEJM： Teprotumumab用于甲狀腺相關(guān)眼病, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=e6c99e836f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話(huà)題小助手
2020-05-29
